Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: Antidiabetic drugs as geroprotectors and anticarcinogens

Annals of the New York Academy of Sciences

Volumn 1057, Issue , 2005, Pages 220-234

  Anisimov, Vladimir N ^a   Berstein, Lev M ^a   Popovich, Irina G ^a   Zabezhinski, Mark A ^a   Egormin, Peter A ^a   Tyndyk, Margarita L ^a   Anikin, Ivan V ^a   Semenchenko, Anna V ^a   Yashin, Anatoli I ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b DUKE UNIVERSITY   (United States)

Author keywords

Antidiabetic drugs; Cancer; IGF 1; Insulin; Life span

Indexed keywords

9BETA DIETHYLAMINOETHYL 2,3 DIHYDROIMIDAZO[1,2 A]BENZIMIDAZOLE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR 2; DIABENOL; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; INSULIN RECEPTOR; METFORMIN; PHENFORMIN; PROTECTIVE AGENT; SOMATOMEDIN C; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AGING; BREAST CANCER; CALORIC RESTRICTION; CANCER; CANCER PREVENTION; CARCINOGENESIS; CONFERENCE PAPER; DROSOPHILA; GENE INACTIVATION; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; LACTIC ACIDOSIS; LIFESPAN; LONGEVITY; MAMMAL; NEMATODE; NONHUMAN; RODENT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

DROSOPHILA MELANOGASTER; MAMMALIA; NEMATODA; RODENTIA;

EID: 32244431832     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1356.017     Document Type: Conference Paper

References (110)

1. BARTKE, A., V. CHANDRASHEKAR, F. DOMINICI, et al. 2003. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology 4: 1-8.
2. TATAR, M., A. BARTKE & A. ANTEBI. 2003. The endocrine regulation of aging by insulin-like signals. Science 299: 1346-1351.
3. FACCHINI, P.S., N.W. HUA, G.M. REAVEN & R.A. STOOHS. 2000. Hyperinsulinemia: the missing link among oxidative stress and age-related diseases? Free Radicals Biol. Med. 29: 1302-1306.
4. ELAHI, D., D.C. MULLER, J.M. EGAN, et al. 2002. Glucose tolerance, glucose utilization, and insulin secretion in aging. Novartis Found. Symp. 242: 222-242.
5. Xu, L. & M.Z. BARD. 1999. Enhanced potential for oxidative stress in hyperinsulinemic rats: imbalance between hepatic peroxisomal hydrogen peroxide production and decomposition due to hyperinsulinemia. Horm. Metab. Res. 31: 278-282.
6. FACCHINI, P.S., N. HUA, F. ABBASI & G.M. REAVEN. 2001. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86: 3574-3578.
7. DILMAN, V.M. 1994. Development, Aging, and Disease: A New Rationale for an Intervention. Harwood Academic. Chur, Switzerland.
8. DILMAN, V.M. 1978. Aging, metabolic immunodepression, and carcinogenesis. Mech. Aging Dev. 8: 153-173.
9. COLANGELO, L.A., S.M. GAPSTUR, R.H. GANN, et al. 2002. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol. Biomarkers Prev. 11: 385-391.
10. GUPTA, K., G. KRISHNASWAMY, A. KARNAD & A.N. PEIRIS. 2002. Insulin: a novel factor in carcinogenesis. Am. J. Med. Sci. 323: 140-145.
11. POLLAK, M.N., E.S. SCHERNHAMMER & S.E. HANKINSON. 2004. Insulin-like growth factors and neoplasia. Nature Rev. Cancer. 4: 505-518.
12. WEINDRUCH, R. & R. WALFORD. 1988. The Retardation of Aging and Disease by Dietary Restriction. C.C. Thomas. Springfield, Ill.
13. ROTH, G.S., D.K. INGRAM & M.A. LANE. 1999. Calorie restriction in primates: Will it work and how will we know? J. Am. Geriatr. Soc. 46: 869-903.
14. CHIBA, T., H. YAMAZA, Y. HIGAMI & I. SHIMOKAWA. 2002. Anti-aging effects of caloric restriction: involvement of neuroendocrine adaptation by peripheral signaling. Microsc. Res. Tech. 59: 317-324.
15. KOUBOVA, J. & L. GUARENTE. 2003. How does calorie restriction work? Genes Dev. 17: 313-321.
16. LONGO, V.D. & C.E. FINCH. 2003. Evolutionary medicine: from dwarf model systems to healthy centenarians. Science 299: 1342-1346.
17. SUN, D., A.R. MUTHUKUMAR, R.A. LAWRENCE & G. FERNANDES. 2001. Effects of calorie restriction on polymicrobial peritonitis induced by cecum ligation and puncture in young C57BL/6 mice. Clin. Diagn. Lab. Immunol. 8: 1003-1011.
18. MASORO, E.J. 2000. Caloric restriction and ageing: an update. Exp. Gerontol. 35: 299-305.
19. MASORO, E.J. 2003. Subfield history: Caloric restriction, slowing aging, and extending life. Science's Sage, K.E. 2003, ns2 (26 February 2003). http://Sageke.sciencemag. org/cgi/content/full/sageke;2003/8/re2.
20. DIK, M.G., S.M. PLUIJM, C. JONKER, et al. 2003. Insulin-like growth factor I (IGF-1) and cognitive decline in older persons. Neurobiol. Aging 24: 573-581.
21. HADLEY, E.C., C. DUTTA, J. FINKELSTEIN, et al. 2001. Human implications of caloric restriction's effect on laboratory animals: an overview of opportunities for research. J. Gerontol. Ser. A 56: 5-6.
22. MATTSON, M.P., W. DUAN, J. LEE, et al. 2001. Progress in the development of caloric restriction mimetic dietary supplements. J. Anti-Aging Med. 4: 225-232.
23. WEINDRUCH, R., K.P. KEENAN, J.M. CARNEY, et al. 2001. Caloric restriction mimetics: metabolic intervention. J. Gerontol. Biol. Sci. 56: 20-33.
24. DILMAN, V.M. 1971. Age-associated elevation of hypothalamic threshold to feedback control and its role in development, aging, and disease. Lancet 1: 1211-1219.
25. DILMAN, V.M. & V.N. ANISIMOV. 1980. Effect of treatment with phenofromin, dyphenylhydantoin, or L-DOPA on life span and tumor incidence in C3H/Sn mice. Gerontology 26: 241-245.
26. ANISIMOV, V.N. 2003. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Exp. Gerontol. 38: 1041-1049.
27. ANISIMOV, V.N., A.V SEMENCHENKO & A.I. YASHIN. 2003. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 4: 297-307.
28. SPASOV, A.A., G.P DUDCHENKO & E.S. GAVRILOVA. 1997. Diabenol-new antidiabetic compounds with haemobiological activity. Vestn. Volgograd Med. Acad. 2: 47-51.
29. ANISIMOVA, V.A., V.V OSIPOVA & A.A. SPASOV. 2002. Synthesis and pharmacological activity of N,N-disubstitutes 3-amino-1H-1,2-diazaohanalenes. Chem. Pharmaceut. J. 36: 11-16.
30. SPASOV, A.A., O.V. OSTROVSKII, I.V. IVAKHNENKO, et al. 1999. The effect of compounds with antioxidant properties on thrombocyte functional activity. Eksp. Klin. Farmakol. 62: 38-40.
31. MEZHERITSKI, V.V., A.L. PIKUS, A.A. SPASOV, et al. 1998. Synthesis and antioxidant activity N.N-substituted 3-amino-1H-1,2-diazophenalenes. Chem. Pharmaceut. J. 1: 15-16.
32. ZINOVIEVA, V.N., O.V. OSTROVSKII, V.A. ANISIMOVA & A.A. SPASOV. 2003. Benzimidazole derivative inhibition of the mutagenic activity of 2-aminoanthracene. Gig. Sanit. 5: 61-63.
33. KIMURA, K.D., H.A. TISSENBAUM, Y. LIU & G. RUVKUN. 1997. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277: 942-946.
34. WOLKOV, C.A., K.D. KIMURA, M.S. LEE & G. RUVKUN. 2000. Regulation of C. elegans life span by insulin-like signaling in the nervous system. Nat. Genetics 290: 147-150.
35. KENYON, C. 2001. A conserved regulatory system for aging. Cell 105: 165-168.
36. CLANCY, D.J., D. GEMS, L.G. HARSHMAN, et al. 2001. Extension of life span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 292: 104-106.
37. TATAR, M., A. KOPELMAN, D. EPSTEIN, et al. 2001. A mutant Drosophila insulin receptor homolog that extends life span and impairs neuroenodcrine function. Science 292: 107-110.
38. DILLIN, A., D.K. CRAWFORD & C. KENYON. 2002. Timing requirements for insulin/IGF-1 signaling in C. elegans. Science 298: 830-834.
39. RICHARDS, J.S., D.L. RUSSELL, S. OCHSNER, et al. 2002. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Prog. Horm. Res. 57: 195-220.
40. ROSSMANITH, W.G. 2001. Neuroendocrinology of aging in the reproductive system: gonadotropin secretion as an example. In Follicular Growth, Ovulation, and Fertilization: Molecular and Clinical Basis. A. Kumar & A.K. Mukhopadhayay, Eds.: 15-25. Narosa Publ. House. New Dehli.
41. FLURKEY, K., J. PAPACONSTANTINOU, R.A. MILLER & D.E. HARRISON. 2001. Life span extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl. Acad. Sci. USA 98: 6736-6741.
42. COSCHIGANO, K.T., D. CLEMMONS, L.L. BELLUSH & J.J. KOPCHICK. 2000. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141: 2608-2613.
43. BARTKE, A. & D. TURYN. 2001. Mechanisms of prolonged longevity: mutants, knockouts, and caloric restriction. J. Anti-Aging Med. 4: 197-203.
44. HSIEH, C.C., J.H. DEFORD, K. FLURKEY, et al. 2002. Implications for the insulin signaling pathway in Snell dwarf mouse longevity: a similarity with the C. elegans longevity paradigm. Mech. Ageing Dev. 123: 1229-1244.
45. HSIEH, C.C., J.H. DEFORD, K. FLURKEY, et al. 2002. Effects of the Pit1 mutation on the insulin signaling pathway: implications on the longevity of the long-lived Snell dwarf mouse. Mech. Ageing Dev. 123: 1245-1255.
46. WEINDRUCH, R. & R.S. SOHAL. 1997. Caloric intake and aging. N. Engl. J. Med. 337: 986-994.
47. ROTH, G.S., D.K. INGRAM & M.A. LANE. 1999. Calorie restriction in primates: will it work and how will we know? J. Am. Geriatr. Soc. 46: 869-903.
48. BARZILAI, N. & G. GUPTA. 1999. Interaction between aging and syndrome X: new insights on the pathophysiology of fat distribution. Ann. NY Acad. Sci. 892: 58-72.
49. DOMINICI, F.P., G. AROSEGUI DIAZ, A. BARTKE, et al. 2000. Compensatory alterations of insulin signal transduction in liver of growth hormone receptor knockout mice. J. Endocrinol. 166: 579-590.
50. DOMINICI, F.P., S. HAUCK, D.P. ARGENTION. et al. 2002. Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (ISR)-1, and IRS-2 in liver of Ames dwarf mice. J. Endocrinol. 173: 81-94.
51. MATTISON, J.M., C. WRIGHT, R.T. BRONSON, et al. 2000. Studies of aging in Ames dwarf mice: effects of caloric restriction. J. Am. Aging Assoc. 23: 9-16.
52. IKENO, Y., R.T. BRONSON, G.B. HUBBARD, et al. 2003. Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J. Gerontol. A Biol. Sci. Med. Sci. 58: B291-B296.
53. LANE, M. A., E.M. TILMONT, H. DE ANGELIS, et al. 2000. Short-term calorie restriction improves disease-related markers in older male rhesus monkeys (Macaca mulatta). Mech. Ageing Dev. 112: 185-196.
54. MATTSON, M.P., W. DUAN, J. LEE, et al. 2001. Progress in the development of caloric restriction mimetic dietary supplements. J. Anti-Aging Med. 4: 225-232.
55. MATTSON, M.P., W. DUAN & N. MASWOOD. 2002. How does the brain control life span? Ageing Res. Rev. 1: 155-165.
56. HOLZENBERGER, M., J. DUPOND, B. DUCOS, et al. 2003. IGF-1 receptor regulates life span and resistance to oxidative stress in mice. Nature 421: 182-187.
57. BLUHER, M., B.B. KAHN & C.R. KAHN. 2003. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299: 572-574.
58. BLUHER, M., M.D. MICHAEL, O.D. PERONI, et al. 2002. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev. Cell 3: 25-38.
59. SHIMOKAWA, I., Y. HIGAMI, M. UTSUYAMA, et al. 2002. Life span extension by reducing growth hormone insulin-growth factor-1 axis in a transgenic rat model. Am. J. Pathol. 160: 2259-2265.
60. ANISIMOV, S.V., M.V. VOLKOVA, L.V. LENSKAYA, et al. 2001. Age-associated accumulation of the apolipoprotein C-III gene T-455C polymorphism C allele in a Russian population. J. Gerontol. Biol. Sci. 56: 27-32.
61. PAOLISSO, G., A. GAMBARDELLA, S. AMMENDOLA, et al. 1996. Glucose tolerance and insulin action in healthy centenarians. Am. J. Physiol. 270: 890-896.
62. BARBIERI, M., M.R. RIZZO, D. MANZELLA, et al. 2003. Glucose regulation and oxidative stress in healthy centenarians. Exp. Gerontol. 38: 137-143.
63. SINGAL, P.K., R.E. BEAMISH & N.S. DHALLA. 1983. Potential oxidative pathways of catecholamine in the formation of lipid peroxides and genesis of heart disease. Adv. Exp. Biol. Med. 161: 391-401.
64. RUIZ-TORRES, A. & M. SOARES DE MELO KIRZNER. 2002. Ageing and longevity are related to growth hormone/insulin-like growth factor-1 secretion. Gerontology 48: 401-407.
65. ROTH, G.S., M.A. LANE, D.K. INGRAM, et al. 2002. Biomarkers of caloric restriction may predict longevity in humans. Science 297: 811.
66. MUNTONI, S. 1974. Inhibition of fatty acid oxidation by biguanides: implication for metabolic physiopathology. Adv. Lipid Res. 12: 311-377.
67. MUNTONI, S. 1999. Metformin and fatty acids. Diabetes Care. 22: 179-180.
68. DILMAN, V.M., L.M. BERSTEIN, M.N. OSTROUMOVA, et al. 1982. Metabolic immunodepression and metabolic immunotherapy. Oncology 39: 13-19.
69. DILMAN, V.M., L.M. BERSTEIN, T.P. YEVTUSHENKO, et al. 1988. Preliminary evidence on metabolic rehabilitation in cancer patients. Arch. Geschwulstforsch. 58: 175-183.
70. BERSTEIN, L.M., T.P. EVTUSHENKO, E.V. TSYRLINA, et al. 1992. Comparative study of five- and ten-year-long results of the metabolic rehabilitation of cancer patients. In Neuroendocrine System, Metabolism, Immunity, and Cancer: Clinical Aspects. K.P. Hanson & V.M. Dilman, Eds.: 102-112. N. N. Petrov Research Institute of Oncology. St. Petersburg.
71. POPOVICH, I.G., M.A. ZABEZHINSKI, P.A. EGORMIN, et al. 2005. Insulin in aging and cancer: new antidiabetic drug Diabenol as geroprotector and anticarcinogen. Int. J. Biochem. Cell Biol. 37: 1117-1129.
72. ANISIMOV, V.N., P.A. EGORMIN, L.M. BERSTEIN, et al. 2005. Metformin slows down aging and development of mammary tumors in transgenic HER-2/neu mice. Bull. Exp. Biol. Med. 139: 961-965.
73. ANISIMOV, V.N. 1982. Effect of phenformin on life span, estrus function, and spontaneous tumor incidence in rats. Farmakol. Toksikol. 45: 127.
74. ANISIMOV, V.N. 1987. Carcinogenesis and Aging, Vol. 2. CRC Press. Boca Raton, Florida.
75. ANISIMOV, V.N. 1980. Effect of buformin and diphenylhydantoin on life span, estrus function, and spontaneous tumor incidence in female rats. Vopr. Onkol. 26: 42-48.
76. BAKAEV, V.V 2002. Effect of 1-butylbiguanide hydrochloride on the longevity in the nematoda Caenorhabditis elegans. Biogerontology 3: 23-24.
77. ANISIMOV, V.N. & V.M. DILMAN. 1975. The increase of hypothalamic sensitivity to the inhibition by estrogens induced by the treatment with L-DOPA, diphenylhydantoin, or phenformin in old rats. Bull. Exp. Biol. Med. 80: 96-98.
78. DILMAN, V.M. & V.N. ANISIMOV. 1979. Hypothalamic mechanisms of aging and of specific age pathology. I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Exp. Gerontol. 14: 161-174.
79. HUNG, A.J., M.G. STANBURY, M. SHANABROUGH, et al. 2003. Estrogen, synaptic plasticity, and hypothalamic reproductive aging. Exp. Gerontol. 38: 53-59.
80. YAGHMAIE, F., S.A. GARAN, M. MASSARO & P.S. TIMIRAS. 2003. A comparison of estrogen receptor-alpha immunoreactivity in the arcuate hypothalamus of young and middle-aged C57BL6 female mice. Exp. Gerontol. 38: 220.
81. AWARTANI, K.A. & A.P. CHEUNG. 2002. Metformin and polycystic ovary syndrome: a literature review. J. Obstet. Gynecol. Can. 24: 393-401.
82. NESTLER, J.E., D. STOVALL, N. AKHTHER, et al. 2002. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril. 77: 209-215.
83. FERNANDES, M.L., M.J. SAAD & L.A. VELLOSO. 2001. Effect of age on elements of insulin-signaling pathway in central nervous system of rats. Endocrine 16: 227-234.
84. RICHARDS, J.S., S.C. SHARMA, A.E. FALENDER & Y.H. LO. 2002. Expression of FKHR, FKHRL1, and AFX genes in the rodent ovary: evidence for regulation by IGF-I, estrogen, and the gonadotropins. Mol. Endocrinol. 16: 590-599.
85. McCARTY, M.F. 1994. Longevity effect of chromium picolinate-rejuvenation of hypothalamic function. Med. Hypotheses 3: 253-265.
86. DE BENEDICTIS, G., L. CAROTENUTO, G. CARRIERI, et al. 1998. Gene/longevity association studies at four autosomal loci (REN, THO, PARP, SOD2). Eur. J. Human Gen. 6: 534-541.
87. DEBENEDICTIS, G., Q. TAN, B. JEUNE, et al. 2001. Recent advances in human gene-longevity association studies. Mech. Ageing Dev. 122: 909-920.
88. HUXTABLE, S.J., P.J. SAKER, L. HADDAD, et al. 2000. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles. Diabetes 49: 126-130.
89. WEAVER, J.U., P.G. KOPELMAN & G.A. HITMAN. 1992. Central obesity and hyperinsulinemia in women are associated with polymorphism in the 5′ flanking region of the human insulin gene. Eur. J. Clin. Invest. 22: 265-270.
90. WATERWORTH, D.M., S.T. BENNETT, N. GHARANI, et al. 1997. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 349: 986-990.
91. TYBAIERG-HANSEN, A., I.U. GERDES, K. OVERGAARD, et al. 1990. Polymorphism in 5′ flanking region of human insulin gene. Relationships with atherosclerosis, lipid levels, and age in three samples from Denmark. Arteriosclerosis 10: 372-378.
92. VINNITSKI, V.B. & V.A. IAKIMENKO. 1981. Effect of phenformin, L-DOPA, and parachlorophenylalanine on the immunological reactivity and chemical carcinogenesis in BALB/c mice. Vopr. Onkol. 27: 45-50.
93. DILMAN V.M., L.M. BERSTEIN, M.A. ZABEZHINSKI & V.A. ALEXANDROV. 1974. On the effect of phenformin on the induction of mammary tumors in rats. Vopr. Oncol. Vol. 20: 94-98.
94. DILMAN, V.M., L.M. BERSTEIN, M.A. ZABEZHINSKI, et al. 1978. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch. Geschwulstforsch. 48: 1-8.
95. ANISIMOV, V.N., N.M. BELOUS, I.A. VASILYEVA & V.M. DILMAN. 1980. Inhibitory effect of phenformin on the development of mammary tumors induced by N-nitrosomethylurea in rats. Exp. Onkol. 2: 40-43.
96. ANISIMOV, V.N., M.N. OSTROUMOVA & V.M. DILMAN. 1980. Inhibition of blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female rats by buformin, diphenylhydantoin, polypeptide pineal extract, and L-DOPA. Bull. Exp. Biol. Med. 89: 723-725.
97. ALEXANDROV, V.A., V.N. ANISIMOV, N.M. BELOUS, et al. 1980. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis 1: 975-978.
98. BESPALOV, V.G. & V.A. ALEXANDROV. 1985. Influence of anticarcinogenic agents on the transplacental carcinogenic effect of N-nitroso-N-ethylurea. Bull. Exp. Biol. Med. 100: 73-76.
99. ANISIMOV, V.N., K.M. POZHARISSKI & V.M. DILMAN. 1980b. Effect of phenformin on the blastomogenic action of 1,2-dimethylhydrazine in rats. Vopr. Onkol. 26: 54-58.
100. DILMAN, V.M., B.N. SOFRONOV, V.N. ANISIMOV, et al. 1977. Phenformin elimination of the immunodepression caused by 1,2-dimethylhydrazine in rats. Vopr. Onkol. 23: 50-54.
101. ANISIMOV, V.N., N.M. BELOUS & E.A. PROKUDINA. 1982. Inhibition by phenformin of the radiation carcinogenesis in female rats. Exp. Onkol. 4: 26-29.
102. SCHNEIDER, M.B., H. MATSUZAKI, J. HARORAH, et al. 2001. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120: 1263-1270.
103. DILMAN, V.M. & V.N. ANISIMOV. 1979. Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1 -phenylethylbiguanide (phenformin). Cancer Lett. 7: 357-361.
104. Wu, Y., S. YAKAR, L. ZHAO, et al. 2002. Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Res. 62: 1030-1035.
105. CARACI, F., M. CHISARI, G. FRASCA, et al. 2003. Effects of phenformin on the proliferation of human tumor cell lines. Life Sci. 74: 643-650.
106. BERSTEIN, L.M., J.O. KVATCHEVSKAYA, T.E. POROSHINA, et al. 2004. Insulin resistance, its consequences for clinical course of the disease and possibilities of correction in endometrial cancer. J. Cancer Res. Clin. Oncol. 130: 687-693.
107. BERSTEIN, L.M. 2005. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 224: 203-212.
108. FACCHINI, F.S., M.H. HUMPHREYS, F. ABBASI, et al. 2000. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am. J. Clin. Nutr. 72: 776-779.
109. FACCHINI, F.S., N. HUA, F. ABBASI & G.M. REAVEN. 2001. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 86: 3574-3578.
110. GARGIULO, P., D. CACCESE, P. PIGNATELLI, et al. 2002. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab. Res. Rev. 18: 156-159.